Search clinical trials for: Exenatide Placebo

Total 53712 results

AstraZeneca
Eli Lilly and Company

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United Kingdom
Carl T. Hayden VA Medical Center
American Diabetes Association; Amylin Pharmaceuticals, LLC.

Completed

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

Type 2 Diabetes Mellitus

United States
University at Buffalo
Amylin Pharmaceuticals, LLC.

Completed

Exeantide in Type 2 Diabetes on Insulin

Type 2 Diabetes

United States
AstraZeneca
Eli Lilly and Company

Completed

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Amsterdam UMC, location VUmc
Bristol-Myers Squibb; Eli Lilly and Company

Completed

The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes (Braini-Ex)

Obesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus

Netherlands
AstraZeneca
Eli Lilly and Company

Completed

A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

Type 2 Diabetes Mellitus

Korea, Republic of, Mexico, Germany, Greece, Argentina, India, Australia
AstraZeneca
Eli Lilly and Company

Terminated

Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin

Diabetes Mellitus

United States, Canada
AstraZeneca

Completed

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Diabetes Mellitus

United States, Hungary, Slovakia, South Africa, Poland, Romania
AstraZeneca
Eli Lilly and Company

Completed

A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

Obesity

United States, Puerto Rico
AstraZeneca
Eli Lilly and Company

Completed

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Mexico, United Kingdom, Israel, Puerto Rico, Greece
University at Buffalo
AstraZeneca

Completed

An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

Evaluate Ketogenic Stress

United States
AstraZeneca

Completed

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

Type 2 Diabetes

United States
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

Type 2 Diabetes Mellitus

United States, Romania, Canada, Mexico, South Africa
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide as Monotherapy

Type 2 Diabetes Mellitus

Russian Federation, Romania, United States, India, Puerto Rico
Oregon Health and Science University
Eli Lilly and Company; Amylin Pharmaceuticals, LLC.

Completed

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics (MEXELIN)

Type 2 Diabetes

United States
University Hospital, Caen
Eli Lilly and Company

Unknown

Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes (EXEPUMP)

Type 2 Diabetes

France
AstraZeneca
Eli Lilly and Company

Completed

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

Type 2 Diabetes Mellitus

Korea, Republic of, China, Taiwan, India
University of Aarhus
Eli Lilly and Company; Aarhus University Hospital

Completed

The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET

Type 2 Diabetes

Denmark
Beth Israel Deaconess Medical Center
Eli Lilly and Company; Amylin Pharmaceuticals, LLC.

Completed

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

Obesity | Impaired Glucose Tolerance

United States
AstraZeneca
Eli Lilly and Company

Completed

Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

Type 2 Diabetes

Japan
AstraZeneca
Eli Lilly and Company

Completed

A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Peptron, Inc.

Completed

A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide

Type 2 Diabetes Mellitus

Korea, Republic of
AstraZeneca
Eli Lilly and Company

Completed

Effect on Weight Loss of Exenatide Versus Placebo

Type 2 Diabetes Mellitus

United States
National Institute on Aging (NIA)

Terminated

A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

Mild Cognitive Impairment | Alzheimer's Disease

United States
AstraZeneca

Completed

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Children and Adolescent With Type 2 Diabetes

United States, Hungary, Israel, Mexico, Bulgaria, Ukraine, Kuwait
Yale University

Completed

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

Type I Diabetes

United States
AstraZeneca

Completed

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Austria, Canada, Italy, Netherlands, Spain, United Kingdom, Taiwan, Thailand, Bulgaria, Belgium, Germany, Korea, Republic of, Hungary, Philippines, China, Malaysia, Hong Kong, New Zealand, Argentina, Czechia, Slovakia, Braz... and more
AstraZeneca
Eli Lilly and Company

Completed

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

Type 2 Diabetes Mellitus

United States
Amsterdam UMC, location VUmc

Unknown

Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial) (EXAMI)

Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).

Netherlands
National Institute of Diabetes and Digestive and...

Completed

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

Obesity | Weight Loss

United States
Phoenix VA Health Care System

Unknown

Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
Eli Lilly and Company

Terminated

A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Netherlands, Canada
Merck Sharp & Dohme LLC

Completed

A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)

The Methodology Assessment of Glucose Dependent Insulin Secretion
AstraZeneca
Eli Lilly and Company

Completed

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Fundació Institut de Recerca de l'Hospital de la...
Instituto de Salud Carlos III

Recruiting

Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)

Pituitary Diseases | Hypothalamic Diseases | Hypopituitarism | Social Isolation | Panhypopituitarism | Psychological Disorder | Central Diabetes Insipidus | Oxytocin Deficiency

Spain
OPKO Health, Inc.

Completed

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico, Romania, Poland, Mexico, Greece
GlaxoSmithKline
The General Hospital Corporation d/b/a Massachusetts General Hospital

Terminated

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Type 2 Diabetes Mellitus

United States, Spain, Canada
AstraZeneca

Completed

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

Type 2 Diabetes Mellitus

Canada, United States
AstraZeneca
Eli Lilly and Company

Completed

A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

Type 2 Diabetes Mellitus

Korea, Republic of, China, Japan, Taiwan, India
Beijing Chao Yang Hospital

Completed

The Effect of Exenatide on Fasting Bile Acids

Type 2 Diabetes Mellitus in Obese

China
AstraZeneca

Completed

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes (DURATION-NEO-1)

Diabetes Mellitus, Type 2

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

Type 2 Diabetes

United States
AstraZeneca
Celerion

Completed

Autoinjector Device Assessment Study (BCB119)

Healthy Subjects

United States
Stanford University

Completed

Exenatide and Weight Loss for Diabetes Prevention

Insulin Resistance | Pre Diabetes

Search clinical trials for: Exenatide Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations